# EDGAR Filing Document

**Accession Number:** 0001124804
**File Stem:** 0001193125-25-338313
**Filing Date:** 2025-12
**Character Count:** 9056
**Document Hash:** 51d45024d6321ba95b8d2d788137b50b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-338313.hdr.sgml**: 20251231

**ACCESSION NUMBER**: 0001193125-25-338313

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20251231

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251231

**DATE AS OF CHANGE**: 20251231

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Veradigm Inc.
- **CENTRAL INDEX KEY:** 0001124804
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMPUTER INTEGRATED SYSTEMS DESIGN [7373]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 364372754
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-32085
- **FILM NUMBER:** 251617576

**BUSINESS ADDRESS:**
- **STREET 1:** 222 MERCHANDISE MART PLAZA
- **STREET 2:** SUITE 2024
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60654
- **BUSINESS PHONE:** 3125061200

**MAIL ADDRESS:**
- **STREET 1:** 222 MERCHANDISE MART PLAZA
- **STREET 2:** SUITE 2024
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60654

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
- **DATE OF NAME CHANGE:** 20100824

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ALLSCRIPTS-MISYS HEALTHCARE SOLUTIONS, INC.
- **DATE OF NAME CHANGE:** 20081010

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ALLSCRIPTS HEALTHCARE SOLUTIONS INC
- **DATE OF NAME CHANGE:** 20010124

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## FORM 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** December 31, 2025<br>

------

VERADIGM INC.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 000-32085 | 36-4392754 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 222 Merchandise Mart |  |  |
| Chicago**,** Illinois |  | 60654 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** 800 334-8534<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common Stock, par value $0.01 per share | MDRX | N/A (OTC Expert Market) |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

## Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
As previously disclosed, on December 8, 2023, Veradigm Inc. (the "Company") announced the appointment of Mr. Leland Westerfield as the Company's Interim Chief Financial Officer, to serve as the Company's principal financial officer and principal accounting officer, effective December 7, 2023, for an initial term of six months through June 7, 2024, and on May 27, 2024, December 31, 2024, and on April 22, 2025, the Company and Mr. Westerfield entered into extension letter agreements with Mr. Westerfield which extended his employment with the Company as Interim Chief Financial Officer through December 31, 2024, June 30, 2025, and December 31, 2025, respectively. On December 31, 2025, the Company entered into an additional extension letter agreement with Mr. Westerfield to further extend his employment through June 30, 2026 (the "Fourth Extension Agreement").

The Fourth Extension Agreement also provides that, in the event of a termination of Mr. Westerfield's employment (other than a termination by the Company for cause or a resignation by Mr. Westerfield that is not for good reason), subject to his execution of a mutually agreeable consulting agreement with the Company and a non-revocation of a release of claims in favor of the Company, Mr. Westerfield is entitled to continue receiving base salary compensation through June 30, 2026, and for an additional six-month period ending December 31, 2026.

The above description of the Fourth Extension Agreement is not complete and is qualified in its entirety by reference to the full text of the Fourth Extension Agreement, which is included as Exhibit 10.1 hereto and incorporated by reference herein.

**Item 7.01 Regulation FD Disclosure.**

The Company has retained a nationally recognized executive search firm and initiated a search process for a permanent Chief Financial Officer.

## Item 9.01 Financial Statements and Exhibits.
*(d) Exhibits.* 

---

| | |
|:---|:---|
| **Exhibit<br>No.** |  |
| 10.1 | [<u>Letter Agreement, dated December 31, 2025, by and between Veradigm Inc. and Leland Westerfield</u>](mdrx-ex10_1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | **VERADIGM INC.** |
| Date: | December 31, 2025 | By:  | /s/ Eric Jacobson |
|  |  |  | Eric Jacobson<br>Senior Vice President, <br>Deputy General Counsel & Corporate Secretary |

---

------

## Exhibit 10.1

![img236491495_0.jpg](img236491495_0.jpg)

December 31, 2025

Leland Westerfield

Re: <u>Renewal Agreement</u>

Dear Lee:

This letter confirms our mutual agreement to extend the term of your employment as Interim Chief Financial Officer and Interim Chief Accounting Officer of Veradigm Inc. (the "<u>Company</u>") under the Letter Agreement, dated December 7, 2023, between you and the Company (the "<u>Letter Agreement</u>") through June 30, 2026 (such term of employment, as defined in Section 3.a of the Letter Agreement and as extended pursuant to that certain letter agreement dated May 28, 2024, that certain letter agreement dated December 31, 2024, that certain letter agreement dated April 22, 2025, and this letter, the "<u>Term</u>").

During the Term, the terms and conditions of your employment, as described in the Letter Agreement, will continue to apply. Notwithstanding the foregoing, if the Term ends for any reason other than (a) a termination of your employment by the Company for Cause (as defined in the Letter Agreement) or (b) your resignation from employment with the Company other than for Good Reason (as defined in the Letter Agreement), you will be entitled to receive continued payments of cash compensation pursuant to Section 4 of the Letter Agreement through June 30, 2026 and for an additional six-month period ending December 31, 2026 (the period between the expiration of the Term and December 31, 2026, the "<u>Transition Period</u>") (subject to you (1) or an affiliate of yours executing a consulting agreement mutually agreeable to you and the Company related to the transition of your employment through the Transition Period and (2) executing and not revoking a general release of claims against the Company and its affiliates in a form reasonably satisfactory to the Company, if requested by the Company).

By your signature below, you agree to the extension of the Term as memorialized herein. Except as expressly provided herein, all other terms and conditions of the Letter Agreement shall remain in full force and effect.

Sincerely,

/s/ Dave B. Stevens

Dave B. Stevens

Chairperson of the Compensation Committee

ACCEPTED BY:

/s/ Leland Westerfield

Leland Westerfield

------